ARR-002 / Aarvik Therap, ArriVent - LARVOL DELTA

ArriVent to Present Two Preclinical Posters on the EGFR Inhibitor Firmonertinib and on the Novel dual-target MUC16/NaPi2b Tetravalent ADC ARR-002 at the 2026 AACR Annual Meeting (GlobeNewswire) - "Unique structural features of firmonertinib enhance binding and activity against EGFR mutant proteins including ex20ins mutant proteins in cell lines and NSCLC animal models. Superior anti-tumor activity of ARR-002 in ovarian cancer models compared to single-target or bivalent approaches with favorable tolerability underscores best-in-disease ADC potential."

Preclinical • Non Small Cell Lung Cancer • Ovarian Cancer

AV-P138-ADC (ARR-002), a novel MUC16/NaPi2b dual-target tetravalent ADC, for the treatment of ovarian and endometrial cancers (AACR 2026) - "Aarvik Therapeutics and ArriVent BioPharma collaborated on the pre-clinical development of AV-P138-ADC. ArriVent subsequently exercised an option for an exclusive global license to the molecule, now known as ARR-002."

ADC • Endometrial Cancer • Oncology • Ovarian Cancer • Solid Tumor • MUC16 • SLC34A2

Upcoming Milestones:…IND filing for ARR-002 (GlobeNewswire) - "U.S. IND filing for first-in-class ADC program planned for first half 2026. Plan to present preclinical data at an upcoming conference."

IND • Preclinical • Solid Tumor

Aarvik Therapeutics Announces Option Exercise by Collaboration Partner ArriVent BioPharma (Businesswire) - "Aarvik Therapeutics...is pleased to announce that its collaboration partner ArriVent BioPharma, Inc. has exercised the option to exclusively license the collaboration program. As part of the research collaboration agreement entered into between Aarvik and ArriVent on December 21, 2021, Aarvik has been responsible for discovery and preclinical development of a novel ADC molecule that relies on the unique modular platform developed by Aarvik. ArriVent will be responsible for clinical development and commercialization."

Licensing / partnership • Oncology